Alaunos Therapeutics (TCRT) Change in Cash (2009 - 2026)

Alaunos Therapeutics (TCRT) has 18 years of Change in Cash data on file, last reported at -$1.0 million in Q1 2026.

• Quarterly Change in Cash fell 33.55% year-over-year to -$1.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $35000.0 (up 100.91% YoY) and the FY2025 annual result came in at $294000.0, up 105.91% from the prior year.
• Change in Cash eased to -$1.0 million in Q1 2026, from -$553000.0 in the prior quarter.
• In the past five years, Change in Cash ranged from a high of $2.6 million in Q2 2025 to a low of -$19.1 million in Q2 2023.
• A 5-year average of -$4.5 million and a median of -$1.7 million in 2024 frame the typical range for Change in Cash.
• Annual changes were most pronounced in 2023 — Change in Cash plunged 570.18% — and 2025, when it soared 252.29%.
• Tracing TCRT's Change in Cash over 5 years: stood at $1.3 million in 2022, then sank by 570.18% to -$5.9 million in 2023, then jumped by 89.94% to -$592000.0 in 2024, then advanced by 6.59% to -$553000.0 in 2025, then plunged by 86.44% to -$1.0 million in 2026.
• The last three Change in Cash figures came in at -$1.0 million (Q1 2026), -$553000.0 (Q4 2025), and -$941000.0 (Q3 2025), per Business Quant data.